View Future GrowthWaters 과거 순이익 실적과거 기준 점검 0/6Waters의 수입은 연평균 -3.1%의 비율로 감소해 온 반면, Life Sciences 산업은 수입이 연평균 4.9% 증가했습니다. 매출은 연평균 3.9%의 비율로 증가해 왔습니다. Waters의 자기자본이익률은 2.9%이고 순이익률은 11.9%입니다.핵심 정보-3.10%순이익 성장률-2.51%주당순이익(EPS) 성장률Life Sciences 산업 성장률26.83%매출 성장률3.92%자기자본이익률2.94%순이익률11.93%최근 순이익 업데이트04 Apr 2026최근 과거 실적 업데이트Reported Earnings • May 08First quarter 2026 earnings released: US$0.88 loss per share (vs US$2.04 profit in 1Q 2025)First quarter 2026 results: US$0.88 loss per share (down from US$2.04 profit in 1Q 2025). Revenue: US$1.27b (up 92% from 1Q 2025). Net loss: US$72.0m (down 159% from profit in 1Q 2025). Revenue is forecast to grow 15% p.a. on average during the next 3 years, compared to a 9.5% growth forecast for the Life Sciences industry in Europe.Reported Earnings • Feb 13Full year 2025 earnings released: EPS: US$10.80 (vs US$10.75 in FY 2024)Full year 2025 results: EPS: US$10.80 (up from US$10.75 in FY 2024). Revenue: US$3.17b (up 7.0% from FY 2024). Net income: US$642.6m (flat on FY 2024). Profit margin: 20% (down from 22% in FY 2024). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 16% p.a. on average during the next 3 years, compared to a 9.4% growth forecast for the Life Sciences industry in Europe.공시 • Jan 27Waters Corporation to Report Q4, 2025 Results on Feb 09, 2026Waters Corporation announced that they will report Q4, 2025 results on Feb 09, 2026공시 • Oct 01Waters Corporation to Report Q3, 2025 Results on Nov 04, 2025Waters Corporation announced that they will report Q3, 2025 results on Nov 04, 2025모든 업데이트 보기Recent updatesReported Earnings • May 08First quarter 2026 earnings released: US$0.88 loss per share (vs US$2.04 profit in 1Q 2025)First quarter 2026 results: US$0.88 loss per share (down from US$2.04 profit in 1Q 2025). Revenue: US$1.27b (up 92% from 1Q 2025). Net loss: US$72.0m (down 159% from profit in 1Q 2025). Revenue is forecast to grow 15% p.a. on average during the next 3 years, compared to a 9.5% growth forecast for the Life Sciences industry in Europe.공시 • May 06Waters Corporation Provides Earnings Guidance for the Second Quarter Ending July 4, 2026 and Full Year Ending December 31, 2026Waters Corporation provided earnings guidance for the second quarter ending July 4, 2026 and full year ending December 31, 2026. For the quarter, the company expects total revenue for the second quarter of 2026 is expected to be in the range of $1.616 billion to $1.631 billion. For the year, the company expects total revenue to be to be in the range of $6.405 billion to $6.455 billion on a reported basis.공시 • Apr 15Waters Corporation Debuts Industry-First Extended-Range MALS Detector for UHPLC/UPLC Powering Rapid Characterization of Large MoleculesWaters Corporation announced the launch of the Waters omniDAWN Multi-Angle Light Scattering (MALS) Photometer, part of the Wyatt Technology Portfolio. Featuring 18 angles of detection, the omniDAWN Photometer is the first extended-range MALS detector for Ultra High Performance Liquid Chromatography (UHPLC) and Ultra Performance Liquid Chromatography (UPLC) workflows, delivering absolute molar mass and size measurements without compromising resolution or throughput. The omniDAWN MALS Photometer extends UPLC-compatible sizing ten-fold, from approximately 50 to 500 nm in radius, enabling reliable characterization of larger, more complex analytes such as protein aggregates, viral vectors, lipid nanoparticles (LNPs), and advanced materials. Because it provides absolute molar mass and size, the omniDAWN Photometer reduces reliance on column calibration standards and supports faster results and more confident comparisons, streamlining work across biosimilarity studies, antibody-drug conjugate (ADC) characterization, and viral vector analytics. Integrating seamlessly with Waters UPLC Systems and columns, the omniDAWN Photometer eliminates traditional trade-offs between dispersion, robustness, and analytical performance, delivering a complete solution for multi-attribute characterization with improved usability compared to micro-volume MALS approaches. When paired with UHPLC or UPLC Systems, the omniDAWN Photometer supports run times up to four times faster than conventional HPLC workflows, while reducing sample consumption by 30–50% and solvent use by approximately 40%. Its low dispersion design preserves resolution and sensitivity, while delivering high-quality data across complex samples. Sharper separations enhance the detection of low-level species, helping scientists distinguish monomer, aggregates, and fragments with greater clarity, supporting informed decision-making across discovery, development, and quality workflows. The omniDAWN Photometer is powered by ASTRA Software, built on more than 40 years of light scattering innovation. By integrating MALS with ultraviolet (UV) and refractive index (RI) detection, ASTRA Software enables comprehensive analysis of size, composition, and heterogeneity in a single run, with dedicated workflows for ADCs, LNPs, and viral vectors. The platform is 21 CFR Part 11 and EU Annex 11 compliant and will be compatible with Waters Empower Software later this year. The Waters omniDAWN MALS Photometer will be available globally in summer 2026.공시 • Apr 10Waters Corporation, Annual General Meeting, May 21, 2026Waters Corporation, Annual General Meeting, May 21, 2026.공시 • Apr 08Waters Corporation Announces U.S. Food and Drug Administration Clearance of the Most Comprehensive At-Home Cervical Cancer Screening Tool, the Onclarity HPV Self-Collection Kit and FDA-Approved HPV AssayWaters Corporation announced that the U.S. Food and Drug Administration (FDA) has cleared the Onclarity HPV Self-Collection Kit and approved the BD Onclarity HPV Assay with extended genotyping for at-home use, marking a significant milestone in expanding access to cervical cancer screening, and removing barriers that currently prevent many individuals from receiving routine screening. Cervical cancer is largely preventable with regular screening and early detection of human papillomavirus (HPV), the virus responsible for nearly all cervical cancers. Approximately 60% of cervical cancer cases occur in individuals who are unscreened or under-screened. Expanding screening options and access, including at-home self-collection, has been identified by public health experts as an instrumental strategy for improving early detection and reducing cervical cancer deaths. The kit is tested with the BD Onclarity HPV Assay, which detects all of the high-risk, carcinogenic genotypes of HPV and is the only FDA-approved HPV assay to identify six individually and three groups of pooled results, making it the most comprehensive HPV screening tool available in the U.S. today. Samples are processed on the fully automated BD COR System, which uses advanced robotics to prepare, analyze, and report results while preserving specimen integrity and ensuring reliable, high-quality outcomes. Waters collaborated with the National Institutes of Health's (NIH) National Cancer Institute (NCI) through the Cervical Cancer 'Last Mile' Initiative SHIP Trial to evaluate the accuracy of self-collection for HPV testing. Waters is currently establishing partnerships to enable broader nationwide access to the Onclarity HPV Self-Collection Kit, which is expected to be available by prescription in the coming months. Covered by private insurance, Medicaid, and Medicare, the kit can be mailed directly to a patient's home, allowing them to collect a sample at their convenience and mail it to a laboratory for processing. Results are shared with the patient's healthcare provider to guide follow-up and care decisions. The Onclarity HPV Self-Collection Kit, Onclarity HPV Assay, and BD COR System are manufactured by Becton, Dickinson and Company or one of its affiliates or subsidiaries.공시 • Mar 10Waters Corporation Launches ARES-G3 RheometerWaters Corporation launched the ARES-G3 Rheometer, part of the TA Instruments product line. This next-generation rheometer delivers industry-leading speed paired with best-in-class data to accelerate materials research and product development. Capturing up to 25,000 data points per second (10x more than its predecessor) and cutting standard test times by up to 80% through fully integrated Fast Frequency Chirps, the ARES-G3 Rheometer addresses pressing industry limitations. The ARES-G3 Rheometer enables shortened experiment times, increased lab throughput, and previously unobtainable measurements of fast-changing samples in a single test. Because it fully integrates a Fast Frequency Chirps solution into its enhanced TRIOS Software, the ARES-G3 Rheometer eliminates the need for multiple software licenses and training in advanced programming packages to capture and process data through rapid frequency sweeps. Routine quality control tests and data generation can also be completed up to 80% faster than before with some tests reduced from six hours to one; this translates to accelerated workflows that save teams hundreds of workdays per year under typical conditions, without sacrificing data quality. The ARES-G3 Rheometer can also perform many tests without requiring user calibrations, reducing margin for human error and increasing confidence in measurements. The ARES-G3 Rheometer builds on the flagship legacy of its predecessor, improving at-instrument control with a new touchscreen, enhancing data capture with hardware and software updates, and preserving its core proprietary, fully integrated dynamic mechanical analysis (DMA) capabilities and purpose-built hardware for both stress measurement and strain control. Retaining the best-in-class oven of the ARES-G2 Rheometer, this next-generation rheometer delivers low-oxygen atmosphere control and temperature uniformity, further simplifying the process of simulating real-world processing conditions, and enabling scientists to explore new rheological methods and gain a deeper understanding of structure-property relationships. All existing ARES-G2 Rheometer methods and fixtures remain fully compatible with the ARES-G3 Rheometer. The Waters TA Instruments ARES-G3 Rheometer is available for order.New Risk • Feb 15New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 65% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (9.6% average weekly change). Shareholders have been substantially diluted in the past year (65% increase in shares outstanding).Reported Earnings • Feb 13Full year 2025 earnings released: EPS: US$10.80 (vs US$10.75 in FY 2024)Full year 2025 results: EPS: US$10.80 (up from US$10.75 in FY 2024). Revenue: US$3.17b (up 7.0% from FY 2024). Net income: US$642.6m (flat on FY 2024). Profit margin: 20% (down from 22% in FY 2024). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 16% p.a. on average during the next 3 years, compared to a 9.4% growth forecast for the Life Sciences industry in Europe.공시 • Feb 10+ 1 more updateWaters Corporation Provides Earnings Guidance for the First Quarter Ending April 4, 2026 and Full Year Ending December 31, 2026Waters Corporation provided earnings guidance for the first quarter ending April 4, 2026 and full year ending December 31, 2026. For the quarter, the company expects total revenue to be in the range of $1.198 billion to $1.211 billion on a reported basis and GAAP earnings per diluted share to be in the range of $0.05 to $0.15. For the year, the company expects total revenue to be to be in the range of $6.405 billion to $6.455 billion on a reported basis. and GAAP earnings per diluted share to be in the range of $6.63 to $6.83.공시 • Feb 09Waters Corporation Appoints Claire M. Fraser to Its Board of DirectorsWaters Corporation announced the appointment of Claire M. Fraser, Ph.D., to its Board of Directors, effective upon the closing of the transaction. Dr. Fraser is a globally acclaimed genome scientist, with three decades of experience managing large research institutes. Most recently, she served as Director of The Institute for Genome Sciences, which she founded in 2007, at the University of Maryland School of Medicine, where she also served as a Professor of Medicine and Microbiology and Immunology. Dr. Fraser received a B.S. in Biology from Rensselaer Polytechnic Institute in Troy, NY, and a Ph.D. in Pharmacology from the State University of New York at Buffalo.공시 • Jan 27Waters Corporation to Report Q4, 2025 Results on Feb 09, 2026Waters Corporation announced that they will report Q4, 2025 results on Feb 09, 2026공시 • Nov 12Waters Corporation Boosts Lab Productivity and Sample Throughput with Launch of Its Charged Aerosol Detector Designed for Empower SoftwareWaters Corporation announced the launch of its Charged Aerosol Detector (CAD) specifically designed for use with Waters Empower Software. Waters is the global market leader in chromatography software solutions for regulatory filings, as Empower Software is used to submit data for approximately 80% of novel drugs to regulatory authorities. The Waters CAD delivers sensitive, consistent, and reproducible measurement of analytes with little or no UV absorption, including sugars, lipids, impurities, and excipients, often without the need for sample pre-treatment. This makes CAD ideal for characterizing an exceptionally broad range of materials, from small molecule and biopharmaceutical formulations to food additives, nutrients, and environmental pollutants. The Waters CAD delivers competitive dynamic range and sensitivity, alongside optimized compatibility with MaxPeak™? High-Performance Surfaces that mitigate non-specific adsorption. The new detector can be used with a wide range of Waters liquid chromatography systems, including the Alliancetm iS HPLC System, the Arctm HPLC System, and all ACQUITY™? UPLC™? Systems. The seamless integration of this CAD with broadly-adopted Empower Software delivers an enhanced user experience, supported by Waters' leading support and service provision. Issues commonly seen in multi-vendor LC-CAD systems, including challenging set-up and dropped communication between detector and chromatograph - leading to interrupted sample sets and in some cases detector flooding - are significantly reduced when using a Waters LC-CAD configured with Empower CDS. In addition, methods developed for existing CADs can be easily transferred using built-in tools. The introduction of the Waters Charged Aerosol Detect reinforces the Company's commitment to provide the world's widest range of liquid chromatography detectors, all compatible with Empower Software - enabling scientists to fully characterize the physical and chemical properties of molecules within a secure and compliant workflow. Availability: The Waters Charged Aerosoldetector (CAD) is available for pre-order now, with shipments available by April 2026.공시 • Nov 05Waters Corporation Raises Earnings Guidance for the Fourth Quarter and Full Year Ending December 31, 2025Waters Corporation raised earnings guidance for the fourth quarter and full year ending December 31, 2025. For the quarter, The company expects constant currency sales growth in the range of +5.0% to +7.0%. Net of currency translation, fourth quarter 2025 reported sales growth is expected in the range of +5.2% to +7.2%. The company expects GAAP earnings per diluted share in the range of $4.10 - $4.20. The Company is raising its full-year 2025 constant currency sales growth guidance to the range of +6.7% to +7.3%. Net of currency translation, the Company is raising its full-year 2025 reported sales growth to the range of +6.5% to +7.1%. The company expects GAAP earnings per diluted share in the range of $11.10 - $11.20.공시 • Oct 01Waters Corporation to Report Q3, 2025 Results on Nov 04, 2025Waters Corporation announced that they will report Q3, 2025 results on Nov 04, 2025공시 • Aug 04+ 1 more updateWaters Corporation Raises Earnings Guidance for the Full Year 2025Waters Corporation raisedd earnings guidance for the full year 2025. For the quarter, the company expects constant currency sales growth guidance to the range of +5.5% to +7.5%. Net of currency translation, the Company is raising its full-year 2025 reported sales growth to the range of +5.0% to +7.0%.공시 • Jul 15Waters Corporation (NYSE:WAT) entered into a definitive agreement to acquire Biosciences and Diagnostics Solutions Business of Becton Dickinson and Company in a transaction valued at $17.5 billion.Waters Corporation (NYSE:WAT) entered into a definitive agreement to acquire Biosciences and Diagnostics Solutions Business of Becton Dickinson and Company in a transaction valued at $17.5 billion on July 13, 2025. BD’s shareholders are expected to own approximately 39.2% of the combined company, and existing Waters shareholders are expected to own approximately 60.8% of the combined company. BD will also receive a cash distribution of approximately $4 billion prior to completion of the combination, subject to adjustment for cash, working capital, and indebtedness. Waters is expected to assume approximately $4 billion of incremental debt, which would result in a net-debt-to-adjusted EBITDA leverage ratio for the combined company of 2.3x at closing. The transaction is subject to receipt of required regulatory approvals, Waters shareholder approval, Any applicable waiting period under the HSR Act and satisfaction of other customary closing conditions. It was subject to approval by Boards of Directors of Waters and BD and has been unanimously approved by the Boards of Directors of both Waters and BD. The transaction is expected to close around the end of the first quarter of calendar year 2026. Upon closing of the transaction, Udit Batra will lead the new entity, and Amol Chaubal will serve as SVP and Chief Financial Officer. Executives from both companies will serve in key leadership roles to be announced at a later date. Up to two BD designees will join the Waters Board of Directors upon closing. The combined company will continue to operate under the Waters name and retain its listing on the New York Stock Exchange under the ticker symbol WAT. Waters’ headquarters will remain in Milford, Massachusetts. Barclays is serving as financial advisor and Daniel E. Wolf, P.C., David M. Klein, P.C., Allie M. Wein, P.C. and Steven M. Choi of Kirkland & Ellis LLP is serving as legal advisor to Waters. Citi and Evercore is acting as lead financial advisor to BD. David K. Lam and Jenna E. Levine of Wachtell, Lipton, Rosen & Katz is serving as legal advisor to BD.공시 • May 23Waters Corporation (NYSE:WAT) acquired Halo Labs.Waters Corporation (NYSE:WAT) acquired Halo Labs on May 21, 2025. Halo Labs, Aura, and Wyatt Technology are trademarks of Waters Technologies Corporation. Waters Corporation (NYSE:WAT) completed the acquisition of Halo Labs on May 21, 2025.공시 • May 21Waters Corporation (NYSE:WAT) acquired Optofluidics, Inc.Waters Corporation (NYSE:WAT) acquired Optofluidics, Inc. on May 21, 2025. Waters Corporation (NYSE:WAT) completed the acquisition of Optofluidics, Inc. on May 21, 2025.매출 및 비용 세부 내역Waters가 돈을 벌고 사용하는 방법. 최근 발표된 LTM 실적 기준.순이익 및 매출 추이BIT:1WAT 매출, 비용 및 순이익 (USD Millions)날짜매출순이익일반관리비연구개발비04 Apr 263,77045087624431 Dec 253,16564374519627 Sep 253,10664870419628 Jun 253,04666168618829 Mar 252,98465767218531 Dec 242,95863867318328 Sep 242,90562367918029 Jun 242,87759666917730 Mar 242,90960467117731 Dec 232,95664269117530 Sep 232,99565369017901 Jul 232,99267569618001 Apr 232,96668968217831 Dec 222,97270865817601 Oct 222,95069765817102 Jul 222,90170264517002 Apr 222,86870564117131 Dec 212,78669362716802 Oct 212,73669560616503 Jul 212,67166056315803 Apr 212,50961654114431 Dec 202,36552255514126 Sep 202,29550450713827 Jun 202,27851552413828 Mar 202,35853752214331 Dec 192,40759252614328 Sep 192,40557758214429 Jun 192,40658058414530 Mar 192,40359158914431 Dec 182,42059458514329 Sep 182,3925554314030 Jun 182,3805155013931 Mar 182,3422754013631 Dec 172,3092054513330 Sep 172,25154851213001 Jul 172,21253750112701 Apr 172,19053350212731 Dec 162,16752251212501 Oct 162,12549850812102 Jul 162,09949050912102 Apr 162,05746750211931 Dec 152,04246949311903 Oct 152,04046949811904 Jul 152,032467496116양질의 수익: 1WAT는 $168.0M 규모의 큰 일회성 손실이 있어 4th April, 2026까지 지난 12개월 재무 결과에 영향을 미쳤습니다.이익 마진 증가: 1WAT의 현재 순 이익률 (11.9%)은 지난해 (22%)보다 낮습니다.잉여현금흐름 대비 순이익 분석과거 순이익 성장 분석수익추이: 1WAT의 수익은 지난 5년 동안 연평균 3.1% 감소했습니다.성장 가속화: 1WAT은 지난 1년 동안 수익이 감소하여 5년 평균과 비교할 수 없습니다.수익 대 산업: 1WAT은 지난 1년 동안 수익이 감소(-31.6%)하여 Life Sciences 업계 평균(5.4%)과 비교하기 어렵습니다.자기자본이익률높은 ROE: 1WAT의 자본 수익률(2.9%)은 낮음으로 평가됩니다.총자산이익률투하자본수익률우수한 과거 실적 기업을 찾아보세요7D1Y7D1Y7D1YPharmaceuticals-biotech 산업에서 과거 실적이 우수한 기업.View Financial Health기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/05/24 21:49종가2026/05/22 00:00수익2026/04/04연간 수익2025/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Waters Corporation는 39명의 분석가가 다루고 있습니다. 이 중 20명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Catherine Ramsey SchulteBairdCharles ButlerBarclaysLuke SergottBarclays36명의 분석가 더 보기
Reported Earnings • May 08First quarter 2026 earnings released: US$0.88 loss per share (vs US$2.04 profit in 1Q 2025)First quarter 2026 results: US$0.88 loss per share (down from US$2.04 profit in 1Q 2025). Revenue: US$1.27b (up 92% from 1Q 2025). Net loss: US$72.0m (down 159% from profit in 1Q 2025). Revenue is forecast to grow 15% p.a. on average during the next 3 years, compared to a 9.5% growth forecast for the Life Sciences industry in Europe.
Reported Earnings • Feb 13Full year 2025 earnings released: EPS: US$10.80 (vs US$10.75 in FY 2024)Full year 2025 results: EPS: US$10.80 (up from US$10.75 in FY 2024). Revenue: US$3.17b (up 7.0% from FY 2024). Net income: US$642.6m (flat on FY 2024). Profit margin: 20% (down from 22% in FY 2024). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 16% p.a. on average during the next 3 years, compared to a 9.4% growth forecast for the Life Sciences industry in Europe.
공시 • Jan 27Waters Corporation to Report Q4, 2025 Results on Feb 09, 2026Waters Corporation announced that they will report Q4, 2025 results on Feb 09, 2026
공시 • Oct 01Waters Corporation to Report Q3, 2025 Results on Nov 04, 2025Waters Corporation announced that they will report Q3, 2025 results on Nov 04, 2025
Reported Earnings • May 08First quarter 2026 earnings released: US$0.88 loss per share (vs US$2.04 profit in 1Q 2025)First quarter 2026 results: US$0.88 loss per share (down from US$2.04 profit in 1Q 2025). Revenue: US$1.27b (up 92% from 1Q 2025). Net loss: US$72.0m (down 159% from profit in 1Q 2025). Revenue is forecast to grow 15% p.a. on average during the next 3 years, compared to a 9.5% growth forecast for the Life Sciences industry in Europe.
공시 • May 06Waters Corporation Provides Earnings Guidance for the Second Quarter Ending July 4, 2026 and Full Year Ending December 31, 2026Waters Corporation provided earnings guidance for the second quarter ending July 4, 2026 and full year ending December 31, 2026. For the quarter, the company expects total revenue for the second quarter of 2026 is expected to be in the range of $1.616 billion to $1.631 billion. For the year, the company expects total revenue to be to be in the range of $6.405 billion to $6.455 billion on a reported basis.
공시 • Apr 15Waters Corporation Debuts Industry-First Extended-Range MALS Detector for UHPLC/UPLC Powering Rapid Characterization of Large MoleculesWaters Corporation announced the launch of the Waters omniDAWN Multi-Angle Light Scattering (MALS) Photometer, part of the Wyatt Technology Portfolio. Featuring 18 angles of detection, the omniDAWN Photometer is the first extended-range MALS detector for Ultra High Performance Liquid Chromatography (UHPLC) and Ultra Performance Liquid Chromatography (UPLC) workflows, delivering absolute molar mass and size measurements without compromising resolution or throughput. The omniDAWN MALS Photometer extends UPLC-compatible sizing ten-fold, from approximately 50 to 500 nm in radius, enabling reliable characterization of larger, more complex analytes such as protein aggregates, viral vectors, lipid nanoparticles (LNPs), and advanced materials. Because it provides absolute molar mass and size, the omniDAWN Photometer reduces reliance on column calibration standards and supports faster results and more confident comparisons, streamlining work across biosimilarity studies, antibody-drug conjugate (ADC) characterization, and viral vector analytics. Integrating seamlessly with Waters UPLC Systems and columns, the omniDAWN Photometer eliminates traditional trade-offs between dispersion, robustness, and analytical performance, delivering a complete solution for multi-attribute characterization with improved usability compared to micro-volume MALS approaches. When paired with UHPLC or UPLC Systems, the omniDAWN Photometer supports run times up to four times faster than conventional HPLC workflows, while reducing sample consumption by 30–50% and solvent use by approximately 40%. Its low dispersion design preserves resolution and sensitivity, while delivering high-quality data across complex samples. Sharper separations enhance the detection of low-level species, helping scientists distinguish monomer, aggregates, and fragments with greater clarity, supporting informed decision-making across discovery, development, and quality workflows. The omniDAWN Photometer is powered by ASTRA Software, built on more than 40 years of light scattering innovation. By integrating MALS with ultraviolet (UV) and refractive index (RI) detection, ASTRA Software enables comprehensive analysis of size, composition, and heterogeneity in a single run, with dedicated workflows for ADCs, LNPs, and viral vectors. The platform is 21 CFR Part 11 and EU Annex 11 compliant and will be compatible with Waters Empower Software later this year. The Waters omniDAWN MALS Photometer will be available globally in summer 2026.
공시 • Apr 10Waters Corporation, Annual General Meeting, May 21, 2026Waters Corporation, Annual General Meeting, May 21, 2026.
공시 • Apr 08Waters Corporation Announces U.S. Food and Drug Administration Clearance of the Most Comprehensive At-Home Cervical Cancer Screening Tool, the Onclarity HPV Self-Collection Kit and FDA-Approved HPV AssayWaters Corporation announced that the U.S. Food and Drug Administration (FDA) has cleared the Onclarity HPV Self-Collection Kit and approved the BD Onclarity HPV Assay with extended genotyping for at-home use, marking a significant milestone in expanding access to cervical cancer screening, and removing barriers that currently prevent many individuals from receiving routine screening. Cervical cancer is largely preventable with regular screening and early detection of human papillomavirus (HPV), the virus responsible for nearly all cervical cancers. Approximately 60% of cervical cancer cases occur in individuals who are unscreened or under-screened. Expanding screening options and access, including at-home self-collection, has been identified by public health experts as an instrumental strategy for improving early detection and reducing cervical cancer deaths. The kit is tested with the BD Onclarity HPV Assay, which detects all of the high-risk, carcinogenic genotypes of HPV and is the only FDA-approved HPV assay to identify six individually and three groups of pooled results, making it the most comprehensive HPV screening tool available in the U.S. today. Samples are processed on the fully automated BD COR System, which uses advanced robotics to prepare, analyze, and report results while preserving specimen integrity and ensuring reliable, high-quality outcomes. Waters collaborated with the National Institutes of Health's (NIH) National Cancer Institute (NCI) through the Cervical Cancer 'Last Mile' Initiative SHIP Trial to evaluate the accuracy of self-collection for HPV testing. Waters is currently establishing partnerships to enable broader nationwide access to the Onclarity HPV Self-Collection Kit, which is expected to be available by prescription in the coming months. Covered by private insurance, Medicaid, and Medicare, the kit can be mailed directly to a patient's home, allowing them to collect a sample at their convenience and mail it to a laboratory for processing. Results are shared with the patient's healthcare provider to guide follow-up and care decisions. The Onclarity HPV Self-Collection Kit, Onclarity HPV Assay, and BD COR System are manufactured by Becton, Dickinson and Company or one of its affiliates or subsidiaries.
공시 • Mar 10Waters Corporation Launches ARES-G3 RheometerWaters Corporation launched the ARES-G3 Rheometer, part of the TA Instruments product line. This next-generation rheometer delivers industry-leading speed paired with best-in-class data to accelerate materials research and product development. Capturing up to 25,000 data points per second (10x more than its predecessor) and cutting standard test times by up to 80% through fully integrated Fast Frequency Chirps, the ARES-G3 Rheometer addresses pressing industry limitations. The ARES-G3 Rheometer enables shortened experiment times, increased lab throughput, and previously unobtainable measurements of fast-changing samples in a single test. Because it fully integrates a Fast Frequency Chirps solution into its enhanced TRIOS Software, the ARES-G3 Rheometer eliminates the need for multiple software licenses and training in advanced programming packages to capture and process data through rapid frequency sweeps. Routine quality control tests and data generation can also be completed up to 80% faster than before with some tests reduced from six hours to one; this translates to accelerated workflows that save teams hundreds of workdays per year under typical conditions, without sacrificing data quality. The ARES-G3 Rheometer can also perform many tests without requiring user calibrations, reducing margin for human error and increasing confidence in measurements. The ARES-G3 Rheometer builds on the flagship legacy of its predecessor, improving at-instrument control with a new touchscreen, enhancing data capture with hardware and software updates, and preserving its core proprietary, fully integrated dynamic mechanical analysis (DMA) capabilities and purpose-built hardware for both stress measurement and strain control. Retaining the best-in-class oven of the ARES-G2 Rheometer, this next-generation rheometer delivers low-oxygen atmosphere control and temperature uniformity, further simplifying the process of simulating real-world processing conditions, and enabling scientists to explore new rheological methods and gain a deeper understanding of structure-property relationships. All existing ARES-G2 Rheometer methods and fixtures remain fully compatible with the ARES-G3 Rheometer. The Waters TA Instruments ARES-G3 Rheometer is available for order.
New Risk • Feb 15New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 65% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (9.6% average weekly change). Shareholders have been substantially diluted in the past year (65% increase in shares outstanding).
Reported Earnings • Feb 13Full year 2025 earnings released: EPS: US$10.80 (vs US$10.75 in FY 2024)Full year 2025 results: EPS: US$10.80 (up from US$10.75 in FY 2024). Revenue: US$3.17b (up 7.0% from FY 2024). Net income: US$642.6m (flat on FY 2024). Profit margin: 20% (down from 22% in FY 2024). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 16% p.a. on average during the next 3 years, compared to a 9.4% growth forecast for the Life Sciences industry in Europe.
공시 • Feb 10+ 1 more updateWaters Corporation Provides Earnings Guidance for the First Quarter Ending April 4, 2026 and Full Year Ending December 31, 2026Waters Corporation provided earnings guidance for the first quarter ending April 4, 2026 and full year ending December 31, 2026. For the quarter, the company expects total revenue to be in the range of $1.198 billion to $1.211 billion on a reported basis and GAAP earnings per diluted share to be in the range of $0.05 to $0.15. For the year, the company expects total revenue to be to be in the range of $6.405 billion to $6.455 billion on a reported basis. and GAAP earnings per diluted share to be in the range of $6.63 to $6.83.
공시 • Feb 09Waters Corporation Appoints Claire M. Fraser to Its Board of DirectorsWaters Corporation announced the appointment of Claire M. Fraser, Ph.D., to its Board of Directors, effective upon the closing of the transaction. Dr. Fraser is a globally acclaimed genome scientist, with three decades of experience managing large research institutes. Most recently, she served as Director of The Institute for Genome Sciences, which she founded in 2007, at the University of Maryland School of Medicine, where she also served as a Professor of Medicine and Microbiology and Immunology. Dr. Fraser received a B.S. in Biology from Rensselaer Polytechnic Institute in Troy, NY, and a Ph.D. in Pharmacology from the State University of New York at Buffalo.
공시 • Jan 27Waters Corporation to Report Q4, 2025 Results on Feb 09, 2026Waters Corporation announced that they will report Q4, 2025 results on Feb 09, 2026
공시 • Nov 12Waters Corporation Boosts Lab Productivity and Sample Throughput with Launch of Its Charged Aerosol Detector Designed for Empower SoftwareWaters Corporation announced the launch of its Charged Aerosol Detector (CAD) specifically designed for use with Waters Empower Software. Waters is the global market leader in chromatography software solutions for regulatory filings, as Empower Software is used to submit data for approximately 80% of novel drugs to regulatory authorities. The Waters CAD delivers sensitive, consistent, and reproducible measurement of analytes with little or no UV absorption, including sugars, lipids, impurities, and excipients, often without the need for sample pre-treatment. This makes CAD ideal for characterizing an exceptionally broad range of materials, from small molecule and biopharmaceutical formulations to food additives, nutrients, and environmental pollutants. The Waters CAD delivers competitive dynamic range and sensitivity, alongside optimized compatibility with MaxPeak™? High-Performance Surfaces that mitigate non-specific adsorption. The new detector can be used with a wide range of Waters liquid chromatography systems, including the Alliancetm iS HPLC System, the Arctm HPLC System, and all ACQUITY™? UPLC™? Systems. The seamless integration of this CAD with broadly-adopted Empower Software delivers an enhanced user experience, supported by Waters' leading support and service provision. Issues commonly seen in multi-vendor LC-CAD systems, including challenging set-up and dropped communication between detector and chromatograph - leading to interrupted sample sets and in some cases detector flooding - are significantly reduced when using a Waters LC-CAD configured with Empower CDS. In addition, methods developed for existing CADs can be easily transferred using built-in tools. The introduction of the Waters Charged Aerosol Detect reinforces the Company's commitment to provide the world's widest range of liquid chromatography detectors, all compatible with Empower Software - enabling scientists to fully characterize the physical and chemical properties of molecules within a secure and compliant workflow. Availability: The Waters Charged Aerosoldetector (CAD) is available for pre-order now, with shipments available by April 2026.
공시 • Nov 05Waters Corporation Raises Earnings Guidance for the Fourth Quarter and Full Year Ending December 31, 2025Waters Corporation raised earnings guidance for the fourth quarter and full year ending December 31, 2025. For the quarter, The company expects constant currency sales growth in the range of +5.0% to +7.0%. Net of currency translation, fourth quarter 2025 reported sales growth is expected in the range of +5.2% to +7.2%. The company expects GAAP earnings per diluted share in the range of $4.10 - $4.20. The Company is raising its full-year 2025 constant currency sales growth guidance to the range of +6.7% to +7.3%. Net of currency translation, the Company is raising its full-year 2025 reported sales growth to the range of +6.5% to +7.1%. The company expects GAAP earnings per diluted share in the range of $11.10 - $11.20.
공시 • Oct 01Waters Corporation to Report Q3, 2025 Results on Nov 04, 2025Waters Corporation announced that they will report Q3, 2025 results on Nov 04, 2025
공시 • Aug 04+ 1 more updateWaters Corporation Raises Earnings Guidance for the Full Year 2025Waters Corporation raisedd earnings guidance for the full year 2025. For the quarter, the company expects constant currency sales growth guidance to the range of +5.5% to +7.5%. Net of currency translation, the Company is raising its full-year 2025 reported sales growth to the range of +5.0% to +7.0%.
공시 • Jul 15Waters Corporation (NYSE:WAT) entered into a definitive agreement to acquire Biosciences and Diagnostics Solutions Business of Becton Dickinson and Company in a transaction valued at $17.5 billion.Waters Corporation (NYSE:WAT) entered into a definitive agreement to acquire Biosciences and Diagnostics Solutions Business of Becton Dickinson and Company in a transaction valued at $17.5 billion on July 13, 2025. BD’s shareholders are expected to own approximately 39.2% of the combined company, and existing Waters shareholders are expected to own approximately 60.8% of the combined company. BD will also receive a cash distribution of approximately $4 billion prior to completion of the combination, subject to adjustment for cash, working capital, and indebtedness. Waters is expected to assume approximately $4 billion of incremental debt, which would result in a net-debt-to-adjusted EBITDA leverage ratio for the combined company of 2.3x at closing. The transaction is subject to receipt of required regulatory approvals, Waters shareholder approval, Any applicable waiting period under the HSR Act and satisfaction of other customary closing conditions. It was subject to approval by Boards of Directors of Waters and BD and has been unanimously approved by the Boards of Directors of both Waters and BD. The transaction is expected to close around the end of the first quarter of calendar year 2026. Upon closing of the transaction, Udit Batra will lead the new entity, and Amol Chaubal will serve as SVP and Chief Financial Officer. Executives from both companies will serve in key leadership roles to be announced at a later date. Up to two BD designees will join the Waters Board of Directors upon closing. The combined company will continue to operate under the Waters name and retain its listing on the New York Stock Exchange under the ticker symbol WAT. Waters’ headquarters will remain in Milford, Massachusetts. Barclays is serving as financial advisor and Daniel E. Wolf, P.C., David M. Klein, P.C., Allie M. Wein, P.C. and Steven M. Choi of Kirkland & Ellis LLP is serving as legal advisor to Waters. Citi and Evercore is acting as lead financial advisor to BD. David K. Lam and Jenna E. Levine of Wachtell, Lipton, Rosen & Katz is serving as legal advisor to BD.
공시 • May 23Waters Corporation (NYSE:WAT) acquired Halo Labs.Waters Corporation (NYSE:WAT) acquired Halo Labs on May 21, 2025. Halo Labs, Aura, and Wyatt Technology are trademarks of Waters Technologies Corporation. Waters Corporation (NYSE:WAT) completed the acquisition of Halo Labs on May 21, 2025.
공시 • May 21Waters Corporation (NYSE:WAT) acquired Optofluidics, Inc.Waters Corporation (NYSE:WAT) acquired Optofluidics, Inc. on May 21, 2025. Waters Corporation (NYSE:WAT) completed the acquisition of Optofluidics, Inc. on May 21, 2025.